Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

LIMS Master Data Management: How a Risk-Based Change Control Approach Improved Compliance and Audit Readiness

This LabWare 8 project involved many master data objects, including products, materials, specifications, tests, limits, units, and sample templates.

However, teams lacked a shared process for managing changes. They did not always know which documentation, approvals, or Change Control steps were required.

Business users wanted speed and flexibility. Meanwhile, QA and CSV teams needed control, traceability, and risk management.

As a result, some changes received extensive Change Control, while others happened informally. Teams also struggled to explain why different changes followed different paths.

The project therefore focused on risk-based LIMS master data management, aligned with ICH Q9, EU GMP Annex 11, FDA data integrity guidance, and GAMP 5 principles.

Our team created a risk-based master data framework that linked each data category to the appropriate change process.

Challenges Faced

A detailed GAP analysis in Quality Management Systems is essential for identifying process deficiencies effectively.
  • No Consistent Change Process: No standard process existed for LIMS master data changes.
  • No Clear Risk Classification: Teams had not classified master data by quality, release, or patient risk.
  • Inconsistent Change Control: Some changes received extensive formal Change Control, while others were handled informally.
  • Limited Traceability: The process did not consistently document what changed, who changed it, when it changed, and why.
  • Conflicting Stakeholder Needs: Business users wanted fast changes. QA and CSV teams required control, traceability, and documented risk management.
  • Complex LabWare 8 Master Data:The system contained many master data types across products, specifications, tests, workflows, and reference data.
  • GMP and Data Integrity Risks: Incorrect master data could affect specifications, calculations, batch release decisions, and data interpretation.

Zamann Pharma Support’s Approach

  • Catalogue LIMS Master Data: The team listed master data types, including products, materials, specifications, tests, methods, units, workflows, and reference values. It also considered data within interfaces, such as SAP material codes and specification IDs.
  • Group Data Into Categories: Related objects were grouped into categories such as product and specification data, analytical methods, calculations, and reference lists.
  •  Assess Risk by Category: Each category was assessed for potential impact on product quality, patient safety, batch release, shelf life, data integrity, and regulatory reporting. The assessment followed ICH Q9-style thinking around probability, severity, and detectability.
  • Assign Risk Levels: Each category was classified as low, medium, or high risk.
  • Low-risk data had no direct impact on quality decisions. High-risk data directly affected product quality, specifications, batch release, or patient safety.
  • Simplify Low-Risk Changes: Low-risk changes followed a documented ticket or request process without mandatory formal Change Control. Examples included cosmetic naming and certain non-critical reference values.
  • Control Higher-Risk Changes: Medium- and high-risk changes followed a dedicated Master Data Change Control process. This covered risk, impact, regression testing, and required approvals from QA and other relevant functions.
  • Create a Risk and Change Matrix: The team created a living document showing each master data category, its risk level, and the required change pathway.
  • Strengthen Traceability: Where possible, LabWare and connected systems supported audit trails, versioning, and reporting of master data changes.
  • Apply Role-Based Training: Training explained master data risks and the correct change process. Master data stewards, QA approvers, LIMS administrators, and end users received role-specific guidance.

Results Achieved

  • Clear Risk-Based Decisions: Teams gained a defined method for selecting the correct change path based on master data risk.
  • Faster Low-Risk Changes: Low-risk changes could follow a simpler documented process without extensive formal Change Control.
  • Stronger Control of Critical Data: Medium- and high-risk changes received structured assessment, testing, and approval.
  • Consistent Change Control Justification: The Master Data Risk and Change Matrix helped teams explain why different changes followed different control paths.
  • Improved Traceability: The framework defined how to record what changed, who changed it, when it changed, and why.
  • Better Balance Between Speed and Control: Low-risk changes remained efficient, while critical master data received stronger governance.
Laboratory
Digital GMP software systems with audit trail monitoring, lifecycle validation controls, and risk-based data governance supporting inspection readiness.
Services

Digital Solutions for GMP Operations

We support pharmaceutical teams in implementing, maintaining, and optimizing GMP software, data management systems, and computerized workflows that strengthen compliance, data integrity, and operational efficiency.

Read More

Contact Us

Need help? Don't hesitate to get in touch
Zamann pharma support is committed to protecting and respecting your privacy, and we’ll use your personal information to administer your account and to provide the products and services you requested from us.

FAQ

1. Which LabWare master data changes require formal Change Control?

Medium- and high-risk changes require dedicated Master Data Change Control. Examples include specifications, product versions, shelf life, critical limits, calculation rules, and test definitions. Low-risk changes can follow a simpler documented request process.

2. How should GMP teams classify LIMS master data risk?

Teams should assess whether a change could affect product quality, patient safety, batch release, shelf life, data integrity, or regulatory reporting. This case used low, medium, and high-risk categories based on ICH Q9-style risk thinking.

3. What should QA document for critical LIMS master data changes?

QA should document what changed, who changed it, when it changed, and why. For higher-risk changes, the process should also include risk assessment, impact assessment, testing requirements, and appropriate approvals.